The leading cause of mortality in patients with
breast cancer is
metastasis, and
bone morphogenetic protein (BMP) signaling activation regulates
metastasis in
breast cancer. This study explored the genetic and epigenetic modification of
BMP receptor genes associated with metastatic
breast cancer cells using bioinformatics. The genetic and epigenetic alterations of
BMP receptors (BMPR1A, BMPR1B, BMPR2, ACVR2A, ACVR1, ACVR2B, ACVR1B, HJV, and ENG) were examined using cBioportal and methSurv, respectively.
mRNA expression was analyzed using TNM plot and bcgenex, and
protein expression was studied using Human
Protein Atlas. Prognostic value and ROC were investigated using Kaplan-Meier (KM) and ROC plot, respectively. Finally, mutant function was predicted using several databases, including PolyPhen-2, FATHMM, Mutation Assessor, and PredictSNP. Oncoprint analysis showed genetic alterations in BMPR1A (39%), BMPR1B (13%), BMPR2 (34%), ACVR2A (14%), ACVR1 (7%), ACVR2B (13), ACVR1B (35%), HJV (40%), and ENG (33%) across the patients with
breast cancer in The Metastatic
Breast Cancer Project. The
mRNA and
protein levels of BMPR2 were increased in metastatic
breast tumor tissues compared with those in normal and
breast tumor tissues. BMPR1A and BMPR2 showed the highest and lowest levels of epigenetic alterations among the
BMP receptors, respectively. The patients with
breast cancer who had low levels of BMPR2 had a better overall survival (OS) than those with high levels of BMPR2. Functional mutation prediction showed that mutants in BMPR2 (R272L, E274K, and L685F), ACVR2A (S127L), and ACVR1B (R484H), are deleterious, probably damaging, and possess a
cancer phenotype. ROC plot revealed no
BMP receptors correlated with endocrine
therapy sensitivity. BMPR1B, BMPR2, and ACVR2A levels were significantly linked as moderate prediction of anti-HER2, BMPR2, and ACVR1B demonstrated moderate predictive potential for
chemotherapy sensitivity. This study contributed in fully comprehending the significance of genetic and epigenetic alterations in
BMP receptors and BMP signaling in metastatic
breast cancer cells for the development of
breast cancer treatment plans.